- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10. | Genflow Biosciences secures EUR4 million for liver disease treatment | 5 | Alliance News | ||
| 22.10. | Genflow Biosciences PLC: Genflow Secures Non-Dilutive Financial Support | 114 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 22.10. | Genflow Biosciences - Genflow Secures Non-Dilutive Financial Support | 2 | RNS | ||
| 30.09. | Genflow Biosciences PLC Announces Half-year Report | 234 | ACCESSWIRE | LONDON, UNITED KINGDOM / ACCESSWIRE / September 30, 2024 / Genflow (LSE:GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024.Chairman's StatementIt is with... ► Artikel lesen | |
| 30.09. | Genflow Biosciences - Half-year Report | 1 | RNS | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.06. | Genflow Biosciences Plc Announces Result of AGM | 256 | ACCESSWIRE | LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen | |
| 27.06. | Genflow Biosciences - Result of AGM | 1 | RNS | ||
| 27.06. | Genflow Biosciences PLC Announces Strengthening of Pre-Clinical Efforts | 225 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 27.06. | Genflow Biosciences - Strengthening of Pre-Clinical Efforts | 1 | RNS | ||
| 12.06. | Genflow Biosciences PLC Announces Receipt of Grant Funding | 167 | ACCESSWIRE | Receipt of Grant Funding LONDON, UK / ACCESSWIRE / June 12, 2024 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE... ► Artikel lesen | |
| 03.06. | Genflow Biosciences PLC Announces Notice of AGM | 189 | ACCESSWIRE | Genflow Biosciences PlcNotice of Annual General Meeting LONDON, UNITED KINGDOM / ACCESSWIRE / June 3, 2024 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging... ► Artikel lesen | |
| 30.05. | Genflow Biosciences PLC Announces Receipt of Grant Funding | 237 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 10.05. | Genflow Biosciences PLC Announces Holding(s) in Company | 276 | ACCESSWIRE | LONDON, UK / ACCESSWIRE / May 10, 2024 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason for NotificationAn... ► Artikel lesen | |
| 08.05. | XFRA WQ5: WIEDERAUFNAHME/RESUMPTION | 101 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 08.05. | Genflow Biosciences PLC Announces Restoration of Listing | 214 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 07.05. | Genflow Biosciences PLC Announces Final Results | 170 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 02.05. | XFRA WQ5: AUSSETZUNG/SUSPENSION | 129 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGENFLOW BIOSCIENCES... ► Artikel lesen | |
| 01.05. | Genflow Biosciences PLC Announces Temporary Suspension | 382 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 30.04. | Genflow Biosciences PLC Announces Total Voting Rights | 270 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 10.04. | Genflow Biosciences PLC Announces Notification of Major Holdings | 57 | ACCESSWIRE | LONDON, UK / ACCESSWIRE / April 10, 2024 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason for... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,660 | -0,10 % | Biotech Report: Evotec und Qiagen behauptet; US-Sektor legt zu | (shareribs.com) Frankfurt / New York 04.12.2024 - Biotech-Aktien zeigten sich im deutschen Handel überwiegend leichter. Unter anderem gaben 4SC und Vita34 nach. Für Evotec ging es leicht nach oben.... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,250 | +122,34 % | Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival | Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for... ► Artikel lesen | |
| BIONTECH | 114,20 | +2,70 % | BioNTech, Medigene und Bayer: Deutsche Biotech-Unternehmen revolutionieren die Krebstherapie | In der Onkologie stehen spannende neue Entwicklungen an: BioNTech wandelt sich vom Covid-19-Impfstoffhersteller zum Krebsmedikamenten-Spezialisten. Mit der Übernahme des chinesischen Unternehmens Biotheus... ► Artikel lesen | |
| EVOTEC | 8,755 | -0,62 % | INDEX-MONITOR: JPMorgan erwartet Evotec zurück im MDax - Dax unverändert | NEW YORK (dpa-AFX) - Zur Index-Überprüfung der Deutschen Börse an diesem Mittwochabend erwartet die US-Bank JPMorgan Kontinuität im Leitindex Dax . Im MDax DE0008467416>, dem Index für mittelgroße... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,385 | -1,01 % | Recursion Pharmaceuticals, Inc.: Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability | REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed... ► Artikel lesen | |
| QUANTUM-SI | 2,000 | -11,31 % | Quantum-Si Inc - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 18,470 | +2,78 % | Here's Why Summit Therapeutics Stock Price Rose 6% on Friday | ||
| BB BIOTECH | 39,750 | -1,85 % | BB Biotech Aktie: Klare Gewinne sichtbar! | ||
| MODERNA | 40,250 | +2,11 % | Moderna-Aktie: Kurs klettert leicht (40,7473 €) | An der US-amerikanischen Börse liegt die Aktie von Moderna aktuell im Plus. Das Papier notiert zur Stunde bei 43,01 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Moderna: Die Aktie weist... ► Artikel lesen | |
| JANUX THERAPEUTICS | 63,63 | +2,03 % | Janux Therapeutics notches fresh record after $350 million equity raise | ||
| TENAYA THERAPEUTICS | 3,600 | +0,84 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Doses First Patient in RIDGE-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy | TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address Underlying Disease RIDGE-1 Currently Enrolling at Six Centers; Observational... ► Artikel lesen | |
| COGENT BIOSCIENCES | 8,880 | -6,53 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients | 56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of patients had >50% decrease in serum tryptase by... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,530 | -5,53 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 12,570 | -4,41 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| ARCELLX | 88,03 | +7,03 % | Safety Stands Out in Arcellx Cell Therapy's ASH Data, But Don't Overlook Manufacturing Advantages |
Das Unternehmen GENFLOW BIOSCIENCES PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+2,86 %) liegt der Kurs bei 0,018 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.
